Integral Characterization of Defective BDNF/TrkB Signalling in Neurological and Psychiatric Disorders Leads the Way to New Therapies
Open accessThe DOI matches its Crossref record; 211 of the 212 references it cites were found in a registry or an index.
Abstract
Enhancement of brain-derived neurotrophic factor (BDNF) signalling has great potential in therapy for neurological and psychiatric disorders. This neurotrophin not only attenuates cell death but also promotes neuronal plasticity and function. However, an important challenge to this approach is the persistence of aberrant neurotrophic signalling due to a defective function of the BDNF high-affinity receptor, tropomyosin-related kinase B (TrkB), or downstream effectors. Such changes have been already described in several disorders, but their importance as pathological mechanisms has been frequently underestimated. This review highlights the relevance of an integrative characterization of aberrant BDNF/TrkB pathways for the rational design of therapies that by combining BDNF and TrkB targets could efficiently promote neurotrophic signalling.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Recombinant BDNF performs poorly in humans due to rapid degradation, limited brain penetration, and unstable exposure profiles [122,123,125].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [123]
Experimental — accuracy not yet measuredIn the citing paper
“The transcription of BDNF is dependent upon activation of the cyclic adenosine monophosphate (cAMP) response element binding protein (CREB) protein which plays a critical role in LTP and synaptic plasticity142, 143.”
From Dysregulation of adult hippocampal neuroplasticity in major depression: Pathogenesis and therapeutic implications (2022) · cites this paper as [143]
In the citing paper
“These changes decrease BDNF axonal transport, resulting in reduced availability of BDNF within the synaptic cleft and consequently diminished signaling through TrkB receptors [137, 138].”
From Brain-Derived Neurotrophic Factor in Brain Disorders: Focus on Neuroinflammation (2019) · cites this paper as [138]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
Alzheimer's Disease Is a Synaptic Failure
Selkoe, D. J. (2002) · Science · doi:10.1126/science.1074069 · Cited by 4,420
The Neuroendocrinology of Stress: A Never Ending Story
Lightman, S. L. (2008) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.2008.01711.x · Cited by 3,566
A Neurotrophic Model for Stress-Related Mood Disorders
Duman, R. S., & Monteggia, L. M. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.02.013 · Cited by 3,375 · cited 1×
“Simultaneously, it has been shown that the therapeutic effects of antidepressants require the action of the BDNF/TrkB pathway [152] and, furthermore, that centrally administered BDNF provides a similar effect to antidepressants in animal models of depression [153].”
BackgroundNestler, E. J., Barrot, M., DiLeone, R. J., Eisch, A. J., Gold, S. J., & Monteggia, L. M. (2002) · Neuron · doi:10.1016/s0896-6273(02)00653-0 · Cited by 3,217
Exercise: a behavioral intervention to enhance brain health and plasticity
Cotman, C. (2002) · Trends in Neurosciences · doi:10.1016/s0166-2236(02)02143-4 · Cited by 2,739 · cited 1×
“For example, physical exercise evokes a significant increase of BDNF levels in rat hippocampus and cerebral cortex [187] which is mediated by brain uptake of circulating insulin-like growth factor I (IGF-I) [188].”
BackgroundGordon, M. O. (2002) · Archives of Ophthalmology · doi:10.1001/archopht.120.6.714 · Cited by 2,626 · cited 1×
“The most important risk factor for glaucoma is intraocular pressure [169].”
BackgroundTrk Receptors: Roles in Neuronal Signal Transduction
Huang, E. J., & Reichardt, L. F. (2003) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.72.121801.161629 · Cited by 2,537 · cited 1×
“Binding of BDNF to TrkB-FL induces the receptor dimerization and activation, and results in the recruitment of proteins that trigger three main signal transduction cascades which are widely interconnected (Figure 1) [5].”
Background
Cited by
Brain-Derived Neurotrophic Factor in Brain Disorders: Focus on Neuroinflammation
Lima Giacobbo, B., Doorduin, J., Klein, H. C., Dierckx, R. A. J. O., Bromberg, E., & de Vries, E. F. J. (2019) · Molecular Neurobiology · doi:10.1007/s12035-018-1283-6 · Cited by 750
Wang, H., Xu, J., Lazarovici, P., Quirion, R., & Zheng, W. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00255 · Cited by 436
Tartt, A. N., Mariani, M. B., Hen, R., Mann, J. J., & Boldrini, M. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01520-y · Cited by 408
“, MAPK/ERK, PI3K, mTOR) [143] responsible for spine enlargement and glutamate sensitivity [144] (Fig.”
BackgroundEsvald, E.-E., Tuvikene, J., Sirp, A., Patil, S., Bramham, C. R., & Timmusk, T. (2020) · The Journal of Neuroscience · doi:10.1523/jneurosci.0367-19.2019 · Cited by 248
“Dysregulation of BDNF expression in a brain region and cell type-specific manner has been implicated in various neurological and neurodevelopmental disorders and in various neurodegenerative diseases (Zuccato and Cattaneo, 2009; Autry and Monteggia, 2012; Tejeda and Díaz-Guerra, 2017).”
BackgroundThe Role of BDNF in the Neuroimmune Axis Regulation of Mood Disorders
Jin, Y., Sun, L. H., Yang, W., Cui, R. J., & Xu, S. B. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.00515 · Cited by 198
“Signaling Pathway of BDNF in Depression Tyrosine receptor kinase B (TrkB), a member of the tyrosine kinase family, can specifically bind to BDNF with a high affinity (41).”
BackgroundInhibiting TRK Proteins in Clinical Cancer Therapy
Lange, A., & Lo, H.-W. (2018) · Cancers · doi:10.3390/cancers10040105 · Cited by 175
“TRKB, encoded by NTRK2, is activated by BDNF and has been shown to promote neural cell plasticity and survival [13].”
BackgroundThe Brain–Skin Axis in Psoriasis—Psychological, Psychiatric, Hormonal, and Dermatological Aspects
Marek‐Józefowicz, L., Czajkowski, R., Borkowska, A., Nedoszytko, B., Zmijewski, M. A., Cubała, W. J., & Slominski, A. T. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23020669 · Cited by 182
Unfolding the Role of BDNF as a Biomarker for Treatment of Depression
Rana, T., Behl, T., Sehgal, A., Srivastava, P., & BUNGAU, S. G. (2020) · Journal of Molecular Neuroscience · doi:10.1007/s12031-020-01754-x · Cited by 146
“Pro-BDNF exerts its biological effect by binding with pan75 neurotrophin receptors (p75NTR), with low affinity, while mBDNF (mature form) binds with Trk receptors with high affinity (Villanueva 2013; Tejeda and Diaz-Guerra 2017).”
BackgroundThe Role of Altered BDNF/TrkB Signaling in Amyotrophic Lateral Sclerosis
Pradhan, J., Noakes, P. G., & Bellingham, M. C. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00368 · Cited by 146
Chitranshi, N., Dheer, Y., Abbasi, M., You, Y., Graham, S. L., & Gupta, V. (2018) · Current Neuropharmacology · doi:10.2174/1570159x16666180419121247 · Cited by 94
“The BDNF-TrkB signalling pathway has been implicated as a mediator for survival, development and synaptic plasticity of neurodegenerative neurons in POAG [200].”
BackgroundInvestigation of the Molecular Role of Brain-Derived Neurotrophic Factor in Alzheimer’s Disease
Girotra, P., Behl, T., Sehgal, A., Singh, S., & BUNGAU, S. G. (2021) · Journal of Molecular Neuroscience · doi:10.1007/s12031-021-01824-8 · Cited by 92
Fernández‐García, S., Sancho‐Balsells, A., Longueville, S., Hervé, D., Gruart, A., Delgado-Garcia, J. M., Alberch, J., & Giralt, A. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-2615-9 · Cited by 84
Challenges of BDNF-based therapies: From common to rare diseases
Miranda‐Lourenço, C., Ribeiro‐Rodrigues, L., Fonseca‐Gomes, J., Tanqueiro, S. R., Belo, R. F., Ferreira, C. B., Rei, N., Ferreira-Manso, M., de Almeida-Borlido, C., Costa-Coelho, T., et al. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105281 · Cited by 88
Marie, C., Pédard, M., Quirié, A., Prigent‐Tessier, A., Garnier, P. E., Totoson, P., & Demougeot, C. (2018) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x18766772 · Cited by 91
TrkB Truncated Isoform Receptors as Transducers and Determinants of BDNF Functions
Tessarollo, L., & Yanpallewar, S. U. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.847572 · Cited by 89
Gureev, A. P., Popov, V. N., & Starkov, A. A. (2020) · Experimental Neurology · doi:10.1016/j.expneurol.2020.113285 · Cited by 73
“A uthor M anuscript A uthor M anuscript A uthor M anuscript A uthor M anuscript Lin PY, Kavalali ET, Monteggia LM 2018 Genetic Dissection of Presynaptic and Postsynaptic BDNFTrkB Signaling in Synaptic Efficacy of CA3-CA1 Synapses.”
BackgroundInfluentialKouba, B. R., Camargo, A., Gil‐Mohapel, J., & Rodrigues, A. L. S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137077 · Cited by 84
“This polarization contributes to the impairment of signaling pathways that play a crucial role in neuronal survival and synaptic plasticity, such as the brain-derived neurotrophic factor (BDNF)/tropomyosin-related kinase B (TrkB) signaling pathway [26].”
Leschik, J., Lutz, B., & Gentile, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147339 · Cited by 82
Hsu, C., Kuo, T., Liu, W., Chang, C., & Lin, H. (2020) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-019-09903-9 · Cited by 72
“This condition results in impairment of neurotransmission, neuronal survival and plasticity, and the processes of learning and memory (Tejeda and Diaz-Guerra 2017).”
Lee, D., Kim, N., Jeon, S. H., Gee, M. S., Ju, Y., Jung, M., Cho, J. S., Lee, Y., Lee, S., & Lee, J. K. (2022) · Nutrients · doi:10.3390/nu14153125 · Cited by 75
“ext, e analyzed the protein levels of B F and TrkB, hich are i portant for neurogenesis, in the hippoca pi of the ice [28].”
MethodAhmed, S., Kwatra, M., Gawali, B., Panda, S. R., & Naidu, V. G. M. (2020) · APOPTOSIS · doi:10.1007/s10495-020-01645-x · Cited by 73
mTOR signaling as a molecular target for the alleviation of Alzheimer's disease pathogenesis
Rapaka, D., Bitra, V. R., Challa, S. R., & Adiukwu, P. C. (2022) · Neurochemistry International · doi:10.1016/j.neuint.2022.105311 · Cited by 69
Gupta, A. K., Gupta, S., Mehan, S., Khan, Z., Das Gupta, G., & Narula, A. S. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05001-5 · Cited by 59
“Dysregulation and altered expression of neurotrophins and their high-affinity receptors contribute to the development of various neurological diseases [41].”
Sharma, M., Dierkes, T., & Sajikumar, S. (2017) · Aging Cell · doi:10.1111/acel.12634 · Cited by 56
Li, J., Xiao, L., Yan, N., Li, Y., Wang, Y., Qin, X., Zhao, D., Liu, M., Li, N., & Lin, Y. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202104141 · Cited by 59
Sharma, V., Singh, T. G., Kaur, A., Mannan, A., & Dhiman, S. (2022) · Neurochemical Research · doi:10.1007/s11064-022-03755-1 · Cited by 59
Zeng, J., Xie, Z., Chen, L., Peng, X., Luan, F., Hu, J., Xie, H., Liu, R., & Zeng, N. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115994 · Cited by 63
Tejeda, G. S., Esteban-Ortega, G. M., Antonio, E. S., Vidaurre, Ó. G., & Díaz‐Guerra, M. (2019) · EMBO Molecular Medicine · doi:10.15252/emmm.201809950 · Cited by 56
“Although this neurotrophin has been considered for the treatment of neurological and psychiatric disorders, clinical trials with BDNF have been unsuccessful (Tejeda & Diaz-Guerra, 2017).”
InfluentialSelf-citationBDNF-TrkB Signaling in Mitochondria: Implications for Neurodegenerative Diseases
Soman, S. K., Swain, M., & Dagda, R. K. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04357-4 · Cited by 66
Phytochemicals Targeting BDNF Signaling for Treating Neurological Disorders
Singh, A. A., Katiyar, S., & Song, M. (2025) · Brain Sciences · doi:10.3390/brainsci15030252 · Cited by 68
“…(full length), TrkB-T1 In the human brain, the TrkB receptor is expressed in four isoforms: TrkB-FL (full length), TrkB-T1 (truncated), TrkB-Shc (Src-homology 2-domain containing adaptor protein) (lacking a tyrosine kinase domain), and TrkB-T-TK (having a non-functional catalytic domain) [43].”
Beitchman, J. A., Griffiths, D. R., Hur, Y., Ogle, S. B., Bromberg, C. E., Morrison, H. W., Lifshitz, J., Adelson, P. D., & Thomas, T. C. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.01434 · Cited by 55
“The central amygdala mediates the HPA axis response to stress, where changes in circulating corticosterone levels, GR, BDNF, and Trk-B receptor expression have been implicated in the pathology of affective disorders (anxiety-like behavior and posttraumatic stress disorder-like phenotypes) in addition to presynaptic gl…”
BackgroundGeng, X., Wang, Q., Lee, H., Huber, C., Wills, M. V., Elkin, K. B., Li, F., Ji, X., & Ding, Y. (2021) · Molecular Neurobiology · doi:10.1007/s12035-021-02329-6 · Cited by 50
Petry, F. D. S., Hoppe, J. B., Klein, C. P., dos Santos, B. G., Hözer, R. M., Bifi, F., Matté, C., Salbego, C. G., & Trindade, V. M. T. (2020) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2020.108525 · Cited by 45
Cheng, F., Wang, Q., Li, C.-X., Wang, X., Yan, X., & Luo, J. (2019) · Neural Regeneration Research · doi:10.4103/1673-5374.259617 · Cited by 42
Li, C., Wang, X., Yan, J., Cheng, F., Ma, X., Chen, C., Wang, W., & Wang, Q. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/1201624 · Cited by 42
Mitrović, M. M., Selaković, D., Jovicic, N. U., Ljujić, B., & Rosic, G. L. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26104926 · Cited by 45
“This phenomenon has been observed in neurodegenerative diseases, including AD and PD, and results in reduced trophic support and heightened vulnerability of neurons [136–138].”
Xu, W., Cao, J., Zhou, Y., Wang, L., & Zhu, G. (2018) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2018.02.005 · Cited by 37
Targeting tropomyosin receptor kinase for cancer therapy
Miao, Q., Ma, K., Chen, D., Wu, X., & Jiang, S. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.04.053 · Cited by 34
Chiha, W., Bartlett, C. A., Petratos, S., Fitzgerald, M., & Harvey, A. R. (2020) · Experimental Neurology · doi:10.1016/j.expneurol.2019.113167 · Cited by 34
Lai, N., Yu, H.-C., Tseng, H.-Y. H., Hsu, C., Huang, H., & Lu, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041841 · Cited by 33
“The other one is a lowaffinity receptor NGFR, also call p75NTR, for neurite growth and apoptosis [23].”
BackgroundLee, H., Yun, H. J., & Ding, Y. (2021) · Brain Circulation · doi:10.4103/bc.bc_35_21 · Cited by 31
Deniz, B. F., Confortim, H. D., Deckmann, I., Miguel, P. M., Bronauth, L., de Oliveira, B. C., Barbosa, S., Cechinel, L. R., Siqueira, I. R., & Pereira, L. O. (2018) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2018.06.008 · Cited by 31
Sanchez-Mendoza, E. H., Camblor-Perujo, S., Martins Nascentes-Melo, L., Dzyubenko, E., Fleischer, M., Silva de Carvalho, T., Schmitt, L.-I., Leo, M., Hagenacker, T., Herring, A., et al. (2020) · Molecular Neurobiology · doi:10.1007/s12035-020-01927-0 · Cited by 27
“models ofmood disorders [7], which is in linewith our finding of reduced neuronal excitability in response to IFN-α and poly(I:C) exposure.”
BK Channel-Mediated Microglial Phagocytosis Alleviates Neurological Deficit After Ischemic Stroke
Huang, S., Chen, T., Suo, Q., Shi, R., Khan, H. L., Ma, Y., Tang, Y., Yang, G., & Zhang, Z. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.683769 · Cited by 28
Shi, M. Y., Yang, J., Liu, Y., Zhao, H., Li, M., Yang, D., & Xie, Q. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04330-1 · Cited by 34
“After binding to TrKB receptor, BDNF can induce the tyrosine kinase receptor phosphorylation of the TrKB receptor and further activates a series of downstream signaling pathways, thereby protecting neurons [15].”
The functional roles of retromer in Parkinson's disease
Cui, Y., Yang, Z., & Teasdale, R. D. (2018) · FEBS Letters · doi:10.1002/1873-3468.12931 · Cited by 28
“Accordingly, inhibition of BDNF or its downstream receptor, TrkB, increases the sensory of dopaminergic neurons to cytotoxic injury, induces the selective loss of dopaminergic neurons and thus may contribute to PD progression [98].”
BackgroundVanderZwaag, J., Halvorson, T., Dolhan, K., Šimončičová, E., Ben‐Azu, B., & Tremblay, M. (2022) · Neurochemical Research · doi:10.1007/s11064-022-03772-0 · Cited by 30
Zeb, S., Ye, H., Liu, Y., Du, H., Guo, Y., Zhu, Y., Ni, Y., Zhang, H.-L., & Xu, Y. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1060954 · Cited by 30
“Enhancing BDNF/ TRkB signaling could activate the PI3K/Akt pathway (Tejeda and Diaz-Guerra, 2017; Wang et al., 2019).”
BackgroundCrespi, B. J. (2019) · Evolution Medicine and Public Health · doi:10.1093/emph/eoz022 · Cited by 25
“The BDNF-trkB system has been considered as a pharmacological target for both a hyperactive system in autism [61], and for underactivity in schizophrenia and depression [62, 63].”
BackgroundЗайнуллина, Л. Ф., Vakhitova, Y. V., Lusta, A. Y., Гудашева, Т. А., & Середенин, С. Б. (2021) · Scientific Reports · doi:10.1038/s41598-021-87435-0 · Cited by 21
Ma, L., Qu, Z., Luo, X., Han, L., Han, Q., He, J., Luan, X., Wang, B., Sun, Y., & He, B. (2021) · Digestive Diseases and Sciences · doi:10.1007/s10620-020-06817-y · Cited by 20
“BDNF was initially discovered in the nervous system, and when TrkB was activated by BDNF, three intracellular signaling factors were subsequently activated: PLC (phospholipase C), ERK1/2 (Ras/extracellular signal regulated kinase 1 and 2), and PI3K (phosphatidylinositol-3-kinase)/Akt [2].”
BackgroundGenetic Dissection of BDNF and TrkB Expression in Glial Cells
Niu, C., Yue, X., An, J. J., Bass, R., Xu, H., & Xu, B. (2024) · Biomolecules · doi:10.3390/biom14010091 · Cited by 26
“BDNF signals via the tropomyosin-related kinase B (TrkB) receptor to regulate neuronal proliferation, differentiation and survival, and synaptic function [1].”
BackgroundTargeting TrkB–PSD-95 coupling to mitigate neurological disorders
Yang, X., Huang, Y. A., & Marshall, J. J. (2024) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-23-02000 · Cited by 21
“In neurological disorders, in which BDNF levels are reduced, the potentiation of TrkB signaling represents a promising therapeutic approach (Tejeda and Diaz-Guerra, 2017).”
BackgroundIsmail, T. R., Yap, C. G., Naidu, R., Shri, L., & Pamidi, N. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116729 · Cited by 20
Rehman, S., Nabi, B., Pottoo, F. H., Baboota, S., & Ali, J. (2020) · Current Gene Therapy · doi:10.2174/1566523220666200607185903 · Cited by 22
Camargo, A., Dalmagro, A. P., Wolin, I. A. V., Siteneski, A., Zeni, A. L. B., & Rodrigues, A. L. S. (2021) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2021.110371 · Cited by 18
Lee, Y., Lee, H., Bae, C.-H., Seo, J. E., Kim, H.-Y., Koo, S., & Kim, S. (2023) · Journal of Traditional and Complementary Medicine · doi:10.1016/j.jtcme.2023.01.005 · Cited by 17
Fan, C.-H., Lin, C.-W., Huang, H.-J., Lee‐Chen, G., Sun, Y., Lin, W., Chen, C., Chang, K., Su, M., & Hsieh‐Li, H. M. (2020) · Psychopharmacology · doi:10.1007/s00213-020-05602-z · Cited by 19
“Three main pathways are involved in upregulating the activation of transcription CREB and further transcribing the neurotrophic factor BDNF, rasERK, PI3K-Akt, and PLC-CaMKII pathways (Pradhan et al. 2019; Tejeda and Diaz-Guerra 2017).”
BackgroundIwata, K., Wu, Q., Ferdousi, F., Sasaki, K., Tominaga, K., Uchida, H., Arai, Y., Szele, F. G., & Isoda, H. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.573487 · Cited by 19
Cell Reprogramming to Model Huntington’s Disease: A Comprehensive Review
Monk, R., & Connor, B. J. (2021) · Cells · doi:10.3390/cells10071565 · Cited by 21
“However, many of these inhibitors target signalling factors downstream of the TrkB and p75 receptors [160,161].”
BackgroundLi, T., Li, S., Yin, X., Li, X., Ma, C., Guan, Z., & Yang, L. (2024) · Neurochemical Research · doi:10.1007/s11064-024-04129-5 · Cited by 20
“TrkB serves as the high-affinity receptor for BDNF, orchestrating a myriad of cellular events, from neuronal survival and apoptosis to synaptic plasticity pivotal for learning and memory processes and synapse development [32, 33].”
Joshi, P. C., Samineni, R., Bhattacharya, D., Reddy, B. R., Veeraval, L., Das, T., Maitra, S., Wahul, A. B., Karri, S., Pabbaraja, S., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-01297-z · Cited by 17
Does metabolic status affect serum levels of BDNF and MMP-9 in patients with schizophrenia?
Arabska, J., Margulska, A., Strzelecki, D., & Wysokiński, A. (2019) · Nordic Journal of Psychiatry · doi:10.1080/08039488.2019.1658126 · Cited by 15
“found to be lowered in schizophrenia [3].”
BackgroundPromising new pharmacological targets for depression: The search for efficacy
Tsugiyama, L. E., de Moraes, R. C. M., Moraes, Y. A. C., & de Oliveira, J. F. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103804 · Cited by 16
Lee, H. Y., Lee, J. M., Lee, H.-L., Park, J., An, H., Park, E. K., Hwang, S. Y., Yoon, S. L., Hwang, G. Y., Kim, K. N., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02398-2 · Cited by 17
“43,44 49 Moreover, numerous reports emphasize its importance in SCI. 38,50,51 Thus, it is not surprising that BDNF ‒ TrkB signaling is critically involved in neuroregeneration and functional recovery after SCI.”
Kaur, P., Attri, S., Singh, D. P., Rashid, F., Singh, S., Kumar, A., Kaur, H., Bedi, N., & Arora, S. (2023) · Scientific Reports · doi:10.1038/s41598-023-31716-3 · Cited by 14
Loch, A. A., Pinto, M. T. C., Andrade, J. C., de Jesus, L. P., de Medeiros, M. W., Haddad, N. M., van de Bilt, M. T., Talib, L. L., & Gattaz, W. F. (2023) · Psychiatry Research · doi:10.1016/j.psychres.2023.115402 · Cited by 12
Farcas, A., Hindmarch, C. C. T., & Iftene, F. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1234220 · Cited by 16
Antonijevic, M., Dallemagne, P., & Rochais, C. (2024) · Medicinal Research Reviews · doi:10.1002/med.22075 · Cited by 13
“31 Phosphorylation of tyrosine at position 816 induces the binding to PLC ‐ γ , promotes neuronal survival and has a role in neurite outgrowth and synaptic plasticity 29,32 (Figure 2).”
Shereck, E. B., Day, N. S., Awasthi, A., Ayello, J. S., Chu, Y., McGuinn, C. E., van de Ven, C., Lim, M. S., & Cairo, M. S. (2019) · Innate Immunity · doi:10.1177/1753425919846584 · Cited by 12
“In fact, the brain derived neurotrophic factor (BDNF) gene has been shown to have a high affinity to TrkB (a tyrosine kinase) and binding of BDNF to TrkB leads to apoptosis.(55,56) The CB CD56 subset also had increased neurogenic locus homolog protein 2 (NOTCH2) expression, which can lead to apoptosis.”
Azogu, I., Liang, J., & Plamondon, H. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2018.05.002 · Cited by 13
“7,8Dihydroxyflavone), could aid in elucidating the functional roles of these isoforms in homeostatic conditions and mood/ neurological disorders stemming from aberrant BDNF/TrkB signaling pathways (Tejeda and Díaz-Guerra, 2017) and their sex-specific nature.”
Antonijevic, M., Dallemagne, P., & Rochais, C. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.380896 · Cited by 11
Mechanism of N6-Methyladenosine Modification in the Pathogenesis of Depression
Xian, Z., Tian, L., Yao, Z., Cao, L., Jia, Z., & Li, G. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04614-6 · Cited by 11
“Further into the molecular and cellular mechanisms, many factors are associated with neuro-plasticity and depression, among which the most important ones are brain-derived neurotrophic factor (BDNF) [109], glutamate [110], and serotonin [24].”
Antonijevic, M., Charou, D., Ramos, I., Valcárcel, M., Gravanis, A., Villacé, P., Callizot, N., Since, M., Dallemagne, P., Charalampopoulos, I., et al. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115111 · Cited by 13
Radioligands for Tropomyosin Receptor Kinase (Trk) Positron Emission Tomography Imaging
Schirrmacher, R., Bailey, J. J., Mossine, A. V., Scott, P. J. H., Kaiser, L., Bartenstein, P., Lindner, S., Kaplan, D. R., Kostikov, A. P., Fricker, G., et al. (2019) · Pharmaceuticals · doi:10.3390/ph12010007 · Cited by 12
“T2) far exceed that of full length TrkB [29].”
BackgroundLiu, F., Huang, S., Guo, D., Li, X., & Han, Y. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.122222 · Cited by 13
Rahmatkar, S. N., & Singh, D. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-04776-x · Cited by 11
“Aβ also reduces CREB activity by decreasing the expression or function of NMDARs, which subsequently leads to the regulation of CREB dephosphorylation and deactivation indirectly [76].”
Esteban-Ortega, G. M., Torres-Campos, E., & Díaz‐Guerra, M. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-07990-6 · Cited by 11
“…cerebroprotective agent used as an adjunct to reperfusion or, additionally, as an enhancer of therapies for neurological and psychiatric diseases based on the use of BDNF or small size analogues [24], which are challenged by TrkB-FL downregulation and GA damage induced by excitotoxicity.”
Self-citationTargeting cathepsin S promotes activation of OLF1-BDNF/TrkB axis to enhance cognitive function
Lee, H.-W., Chen, S.-J., Tsai, K., Hsu, K., Chen, Y., Chang, C., Lin, H., Hsueh, W.-Y., Hsieh, H., Lee, Y.-F., et al. (2024) · Journal of Biomedical Science · doi:10.1186/s12929-024-01037-2 · Cited by 9
“Low BDNF levels in the brain is associated with the occurrence of various neurological disorders [25].”
BackgroundLima‐Ojeda, J. M., Mallien, A. S., Brandwein, C., Lang, U. E., Hefter, D., & Inta, D. (2018) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-018-0882-6 · Cited by 9
Multiple epigenetic biomarkers for evaluation of students' academic performance
Lee, L., Su, M., Cho, Y., Lee‐Chen, G., Yeh, T., & Chang, C. (2019) · Genes Brain & Behavior · doi:10.1111/gbb.12559 · Cited by 9
“These observations further strengthen the notion that BDNF is one of key mediators in memory processing.(20,21) A previous biochemical analysis of memory-associated proteins showed significant protein changes in BDNF, phospho-CREB protein (p-CREB) and MeCP2.”
BackgroundWala, K., Świerczyńska-Mróz, K., Krajewski, P. K., Nowicka‐Suszko, D., Krajewska, M., & Szepietowski, J. C. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11216292 · Cited by 9
“In contrast, molecules that function as TrkB agonists that may be effective in the treatment of neurological and psychiatric diseases are currently being sought [55].”
BackgroundLi, Y., Haixia, Y., Yuchen, S., Mingxin, Z., Lu, M., Tian, Y., Aizhen, W., & Han, X. (2022) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2022/5471586 · Cited by 10
“0e phospholipase Cc was recruited and activated by phosphorylation of Tyr816 residue for promoting neuronal survival and implicating neurite outgrowth and synaptic plasticity [59].”
BackgroundLv, S., Yang, N., Lu, Y., Zhang, G., Zhong, X., Cui, Y., Huang, Y., Jing, T., & Sai, Y. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1426769 · Cited by 11
Pan, L., Cao, Z., Chen, L., Qian, M., & Yan, Y. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.941973 · Cited by 8
“A large amount of evidence suggests that insufficient neurotrophic supply of cortical neurons may be a potential factor in the pathophysiology of SZ, because normal brain development, maturation and function require adequate neurotrophic support (1, 2).”
BackgroundDevelopment of Pleiotropic TrkB and 5-HT4 Receptor Ligands as Neuroprotective Agents
Antonijevic, M., Charou, D., Davis, A., Curel, T., Valcárcel, M., Ramos, I., Villacé, P., Claeysen, S., Dallemagne, P., Gravanis, A., et al. (2024) · Molecules · doi:10.3390/molecules29020515 · Cited by 8
Ugalde‐Triviño, L., Tejeda, G. S., Esteban-Ortega, G. M., & Díaz‐Guerra, M. (2025) · Theranostics · doi:10.7150/thno.111272 · Cited by 11
“Signaling by brain-derived neurotrophic factor (BDNF)-binding to its high-affinity transmembrane receptor, tropomyosin-related kinase B (TrkB), becomes profoundly aberrant in stroke [9,10].”
Self-citationShao, Q., Li, Y., Jin, L., Zhou, S., Fu, X., Liu, T., Luo, G., Du, S., & Chen, C. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1491900 · Cited by 7
The prognostic value of over-expressed TrkB in solid tumors: a systematic review and meta-analysis
Zhang, C., Li, X., Gao, D., Ruan, H., Li, X., Liu, G., Li, X., Ma, Z., & Li, X. (2017) · Oncotarget · doi:10.18632/oncotarget.19561 · Cited by 6
He, B., Qu, Z., Tian, Z., Zhao, K., Wei, L.-Z., & Ma, L. (2018) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.12999 · Cited by 6
Pérol, M., & Swalduz, A. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.00859 · Cited by 7
Gaber, A. M., El-Bakry, A. M., Aljàrari, R. M., Jaber, F. A., Khadrawy, Y. A., Sabry, D., Abo‐Eleneen, R. E., & Ahmed, O. M. (2023) · Stem Cells International · doi:10.1155/2023/2690949 · Cited by 7
“BDNF promotes neuronal differentiation and survival by suppressing proapoptotic proteins and upregulating neurofunctional proteins through the cyclic adenosine monophosphate response element binding protein transcription pathway [67, 68].”
BackgroundToward Imaging Tropomyosin Receptor Kinase (Trk) with Positron Emission Tomography
Schirrmacher, R., Bernard‐Gauthier, V., Jaworski, C., Wängler, C., Wängler, B., & Bailey, J. J. (2020) · Springer eBooks · doi:10.1007/978-3-030-53176-8_31 · Cited by 4
Type II & III inhibitors of tropomyosin receptor kinase (Trk): a 2020–2022 patent update
Iliev, P., Jaworski, C., Wängler, C., Wängler, B., Page, B. D. G., Schirrmacher, R., & Bailey, J. J. (2024) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2024.2358818 · Cited by 5
“Emerging evidence also indicates that aberrant Trk signaling may play a role in the pathogenesis of neurodegenerative diseases, such as Alzheimer’s ( AD ) and Parkinson’s Disease ( PD ) [26–29].”
BackgroundDosimetry of [18F]TRACK, the first PET tracer for imaging of TrkB/C receptors in humans
Thiel, A., Kostikov, A. P., Ahn, H., Daoud, Y., Soucy, J., Blinder, S. A. L., Jaworski, C., Wängler, C., Wängler, B., Juengling, F. D., et al. (2023) · EJNMMI Radiopharmacy and Chemistry · doi:10.1186/s41181-023-00219-x · Cited by 4
“Within the CNS, reduced expression or abnormal and impaired signalling of Trk receptors are found in a vast spectrum of disorders and pathologies, such as ischemic stroke, Alzheimer’s disease (AD) and others (Tejeda and Díaz-Guerra 2017).”
BackgroundEffects of 7,8‐dihydroxyflavone on rat jejunal dynamics subjected to ischaemia–reperfusion injury
Ma, L., Qu, Z., Luan, X., Jiang, X., Pan, R., Zhao, T., Ma, X., & He, B. (2019) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.13136 · Cited by 4
Excitotoxicity-induced endocytosis as a potential target for stroke neuroprotection
Díaz‐Guerra, M. (2020) · Neural Regeneration Research · doi:10.4103/1673-5374.290892 · Cited by 4
“However, a potential caveat of this approach is that signaling mediated by BDNF is dramatically subverted by excitotoxicity, a process not only central to stroke but, as mentioned, also associated to many other neurological disorders (Tejeda and Diaz-Guerra, 2017).”
Self-citationSefiani, A., Horvat, D., Pewklang, T., Thompson, T., Morey, S., Abdelfattah, A., Samaie, O., Hoar, J., Burgess, K., & Geoffroy, C. G. (2026) · Experimental Neurology · doi:10.1016/j.expneurol.2026.115746 · Cited by 3
Alterations in the plasma concentrations of BDNF, proBDNF, and MMP-9 in patients with schizophrenia
Liang, Y., Pan, H., Yang, Z., Yu, C., Jiang, T., Li, Y., Yu, H., Qiu, M., & Zhang, S. (2025) · European journal of medical research · doi:10.1186/s40001-025-03153-7 · Cited by 5
“The current diagnosis of SCZ primarily relies on clinical presentation and historical assessment, lacking objective biomarkers, which hampers the development of early diagnosis and precision treatment [4, 5].”
Zhu, J., Zou, J., Li, F., Gao, Y., Wang, L., Sun, Y. E., Zhu, J., Zhang, X., Xue, K., Li, G., et al. (2022) · MedComm – Future Medicine · doi:10.1002/mef2.15 · Cited by 4
Metadata
- Authors
- Tejeda, G., & Díaz-Guerra, M.
- Affiliations
- Consejo Superior de Investigaciones Científicas (ES)
- Instituto de Investigaciones Biomédicas “Alberto Sols”, Consejo Superior de Investigaciones Científicas-Universidad Autónoma de Madrid (CSIC-UAM), Arturo Duperier 4, 28029 Madrid, Spain
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2017-01-28
- Volume
- 18
- Issue
- 2
- Pages
- 268
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC5343804
- OpenAlex
- W2581435615
- Cited by
- 126
- References
- 212
- Citations by year
- 2026: 8 · 2025: 13 · 2024: 16 · 2023: 16 · 2022: 13 · 2021: 13 · 2020: 20 · 2019: 13 · 2018: 10 · 2017: 4
- FWCI
- 1.58
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion)
- DIGITAL.CSIC (Spanish National Research Council (CSIC)) (submittedVersion, cc-by)
- Funders
- Ministerio de Economía y Competitividad, Spain (BFU2013-43808-R)
- Fundación Mutua Madrileña, Spain (201322001)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Nerve injury and regeneration
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacological Receptor Mechanisms and Effects
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Keywords
- brain-derived neurotrophic factor, TrkB receptor, BDNF/TrkB signaling, neurotrophin signaling, neurological disorders, mental illness, neurotrophic therapy, neuroplasticity, cell death
- MeSH terms
- Animals, Mental Disorders, Humans, Nervous System, Signal Transduction, Brain-Derived Neurotrophic Factor, Receptor, trkB, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.